

Table 14.2.2.6.1 Comparison of the use of local symptomatic and/or topical antifungal treatment between treatments (PPS)

WHO ATC Code / Name	IMUNOR	PLACEBO
	N = 52	N = 21
	n (%)	n (%)
Any medication with VV indication	26 (50.0)	18 (85.7)
G01AF02 / Clotrimazole	17 (32.7)	12 (57.1)
G01AA51 / Nystatin, combinations	10 (19.2)	7 (33.3)
G01AC05 / Dequalinium	6 (11.5)	3 (14.3)
D01AC01 / Clotrimazole	3 (5.8)	4 (19.0)
D01AC20 / Imidazoles/triazoles in combination with corticosteroids	5 (9.6)	2 (9.5)
G01AF12 / Fenticonazole	4 (7.7)	1 (4.8)
G01AF20 / Combinations of imidazole derivatives	3 (5.8)	2 (9.5)
G01AF05 / Econazole	2 (3.8)	2 (9.5)
G01AX05 / Nifuratel	4 (7.7)	
G01AA02 / Natamycin	2 (3.8)	1 (4.8)
G01AX / Other antiinfectives and antiseptics	2 (3.8)	1 (4.8)
D01AA01 / Nystatin	1 (1.9)	1 (4.8)
D01AA02 / Natamycin	1 (1.9)	1 (4.8)
D03AX / Other cicatrizants	2 (3.8)	
G01AA10 / Clindamycin	1 (1.9)	1 (4.8)
G01AF15 / Butoconazole	2 (3.8)	
G02CC03 / Benzydamine	2 (3.8)	
J01FA10 / Azithromycin	1 (1.9)	1 (4.8)
J01XE01 / Nitrofurantoin	2 (3.8)	
D07AC13 / Mometasone	1 (1.9)	
D07CA01 / Hydrocortisone and antibiotics	1 (1.9)	
G01AX12 / Ciclopirox		1 (4.8)
G04BD04 / Oxybutynin	1 (1.9)	
J01AA02 / Doxycycline	1 (1.9)	
J01CA04 / Amoxicillin		1 (4.8)
J01FF01 / Clindamycin	1 (1.9)	
J01MA06 / Norfloxacin	1 (1.9)	
J01XX01 / Fosfomicin	1 (1.9)	
J02AC01 / Fluconazole	1 (1.9)	
P01AB01 / Metronidazole		1 (4.8)
V07AB / Solvents and diluting agents, incl. irrigating solutions	1 (1.9)	

% = Percentage of subjects out of N; N = Total number of subjects; n = Number of subjects with medication; PPS = Per Protocol Set; VV = Vulvovaginitis.

Coded using WHODrug Global B3 March 1, 2024.

Produced on 07-NOV-2024

Page 1 of 1

Table 14.2.2.6.2 Comparison of the use of local symptomatic and/or topical antifungal treatment between treatments (FAS)

WHO ATC Code / Name	IMUNOR	PLACEBO
	N = 90	N = 46
	n (%)	n (%)
Any medication with VV indication	47 (52.2)	34 (73.9)
G01AF02 / Clotrimazole	25 (27.8)	20 (43.5)
G01AA51 / Nystatin, combinations	17 (18.9)	12 (26.1)
D01AC01 / Clotrimazole	7 (7.8)	6 (13.0)
D03AX / Other cicatrizants	8 (8.9)	5 (10.9)
G01AC05 / Dequalinium	8 (8.9)	5 (10.9)
G01AF20 / Combinations of imidazole derivatives	7 (7.8)	5 (10.9)
D01AC20 / Imidazoles/triazoles in combination with corticosteroids	7 (7.8)	4 (8.7)
G01AX / Other antiinfectives and antiseptics	6 (6.7)	4 (8.7)
D07CA01 / Hydrocortisone and antibiotics	5 (5.6)	4 (8.7)
G01AF15 / Butoconazole	5 (5.6)	3 (6.5)
G01AF12 / Fenticonazole	5 (5.6)	2 (4.3)
G01AF05 / Econazole	3 (3.3)	3 (6.5)
D01AA01 / Nystatin	3 (3.3)	2 (4.3)
G01AX05 / Nifuratel	4 (4.4)	
G02CC03 / Benzydamine	3 (3.3)	1 (2.2)
J02AC01 / Fluconazole	2 (2.2)	2 (4.3)
G01AA02 / Natamycin	2 (2.2)	1 (2.2)
G01AA10 / Clindamycin	2 (2.2)	1 (2.2)
D01AA02 / Natamycin	1 (1.1)	1 (2.2)
J01FA10 / Azithromycin	1 (1.1)	1 (2.2)
J01XE01 / Nitrofurantoin	2 (2.2)	
P01AB01 / Metronidazole		2 (4.3)
D01AC03 / Econazole		1 (2.2)
D07AC13 / Mometasone	1 (1.1)	
D08AD / Boric acid products	1 (1.1)	
G01AA01 / Nystatin	1 (1.1)	
G01AX12 / Ciclopirox		1 (2.2)
G04BD04 / Oxybutynin	1 (1.1)	
J01AA02 / Doxycycline	1 (1.1)	
J01CA04 / Amoxicillin		1 (2.2)
J01CR04 / Sultamicillin	1 (1.1)	
J01FF01 / Clindamycin	1 (1.1)	
J01MA01 / Ofloxacin	1 (1.1)	
J01MA06 / Norfloxacin	1 (1.1)	
J01XX / Other antibacterials		1 (2.2)
J01XX01 / Fosfomicin	1 (1.1)	
M01AB05 / Diclofenac	1 (1.1)	
V07AB / Solvents and diluting agents, incl. irrigating solutions	1 (1.1)	

% = Percentage of subjects out of N; FAS = Full Analysis Set; N = Total number of subjects; n = Number of subjects with medication; VV = Vulvovaginitis.
Coded using WHODrug Global B3 March 1, 2024.

Produced on 07-NOV-2024

Page 1 of 1